Literature DB >> 15164446

Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.

O Glehen1, E Cotte, V Schreiber, A C Sayag-Beaujard, J Vignal, F N Gilly.   

Abstract

BACKGROUND: Colorectal cancer with peritoneal carcinomatosis is usually considered incurable. The purpose of this study was to evaluate the efficacy of intraperitoneal chemohyperthermia (IPCH) following cytoreductive surgery in patients with colorectal carcinomatosis.
METHODS: Between January 1989 and August 2002, 53 patients (mean age 48.6 years) were treated by IPCH with mitomycin C. IPCH was performed in 34 patients following extensive cytoreductive surgery (more than two peritonectomy procedures). Five patients underwent two operations and one patient three operations.
RESULTS: Operative morbidity and mortality rates were 23 and 4 per cent respectively. At a median follow-up of 59.5 months, the overall median survival was 12.8 months. The extent of carcinomatosis, completeness of cytoreduction and histological differentiation were significant prognostic indicators by univariate analysis. The median survival was 32.9 months for patients whose resection was classified as completeness of cancer resection (CCR) 0 (complete cytoreduction), 12.5 months for those whose operation was CCR-1 (diameter of residual nodules 5 mm or less) and 8.1 months for patients who had a CCR-2 resection (diameter of residual nodules more than 5 mm) (P < 0.001). Completeness of cytoreduction was the only significant independent predictor of survival by multivariate analysis.
CONCLUSION: IPCH combined with cytoreductive surgery seems to be an effective therapy for carefully selected patients with carcinomatosis from colorectal cancer. This strategy was most effective in patients with carcinomatosis of limited tumour volume or when cytoreductive surgery allowed sufficient downstaging (residual tumour nodules smaller than 5 mm). Copyright 2004 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164446     DOI: 10.1002/bjs.4473

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  45 in total

1.  Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery.

Authors:  T Adachi; T Hinoi; H Egi; M Shimomura; H Ohdan
Journal:  Surg Today       Date:  2014-08-26       Impact factor: 2.549

2.  Peritoneal carcinomatosis of colorectal origin: standard of care.

Authors:  Tristan D Yan
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

Review 3.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 4.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

5.  Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

Authors:  P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 6.  Current treatment options for colon cancer peritoneal carcinomatosis.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 7.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer.

Authors:  Konstantinos I Votanopoulos; Katrina Swett; Aaron U Blackham; Chukwuemeka Ihemelandu; Perry Shen; John H Stewart; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

9.  Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.

Authors:  P Piso; M H Dahlke; N Ghali; I Iesalnieks; M Loss; F Popp; P von Breitenbuch; A Agha; S A Lang; F Kullmann; H J Schlitt
Journal:  Int J Colorectal Dis       Date:  2007-04-26       Impact factor: 2.571

10.  Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.

Authors:  Laura A Lambert; Terri S Armstrong; J Jack Lee; Suyu Liu; Matthew H G Katz; Cathy Eng; Robert A Wolff; Melissa L Tortorice; Pier Tansey; Santiago Gonzalez-Moreno; Donald H Lambert; Paul F Mansfield
Journal:  Ann Surg Oncol       Date:  2009-05-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.